Eyepoint Inc (EYPT) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eyepoint Inc   (NASDAQ: EYPT)

Eyepoint Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Eyepoint Inc in the second quarter 2026?
Eyepoint Inc recorded a cumulative net loss of $-307 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -135.81%.

Within the Laboratory Analytical Instruments industry 21 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2053 to 3581.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -32.36 % -22.76 % -9.03 % -8.48 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -307 -272 -232 -206 -175
Return On Equity (TTM) -135.81 % -110.54 % -88.31 % -76.13 % -63.8 %
EYPT's Total Ranking # 3581 # 2053 # 3114 # 2865 # 2879
Equity (TTM) in Millions 166 230 306 200 246
Seq. Equity Change -27.8 % -24.71 % 52.92 % -18.63 % -17.56 %
Seq. Net Income Change - - - - -

Back to EYPT Management Effectiveness >> EYPT's 5 Years Annual ROE >> Compare EYPT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 22
Sector # 602
Overall # 3581

Return On Equity Statistics
High Average Low
56.78 %
-136.98 %
-548.28 %
(Sep 30 2014)   (Jun 30 2018)



  News about Eyepoint Inc Return on Equity ROE

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

EyePoint Pharmaceuticals: Strategic Growth and Promising Developments in OphthalmologyIn an era where the pharmaceutical industry faces rigorous competition and rapid advancements, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is making noteworthy progress in its quest to provide innovative solutions for serious retinal diseases. The company’s latest updates reveal a strategic public offering aimed at fueling operational growth, as well as encouraging developments in its clinical trials for groundbreaking therapies.Strong Financial Moves for Sustainable GrowthOn October 29, 2024, EyePoint Pharmaceuticals announced the pricing of an upsized public offering, which reflects its commitment to expanding its capabilities and reach within the healthcare sector. The company plans to offer 12,727,273 shares of its common stock at a price of $11.00 per share, potentially generating approximately $140 million in gross proceeds before subtracting any underwriting discounts and expenses. Importantly, all shares in this offering are being sold by EyePoint itself, which underscores the company’s strategy of leveraging its equity to finance its research and development initiatives.



EYPT Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 306 337 266 96 184
Y / Y Equity Change -9.03 % 26.35 % 176.36 % -47.73 % 894.44 %
Net Income in Millions -232 -131 -71 -102 -58
Y / Y Net Income Change - - - - -
Return On Equity -75.78 % -38.89 % -26.58 % -106.11 % -31.68 %

Back to EYPT Management Effectiveness >> EYPT's 5 Years Annual ROE >> Compare EYPT ROE to its Competitors




More Return On Equity Ratios
Laboratory Analytical Instruments Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
EYPT's' Return on Equity at Yahoo Finance
EYPT's Roe Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for EYPT's Competitors
Subscribers only: Roe for Eyepoint Inc 's Suppliers
Subscribers only: Return On Equity for EYPT's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-10T13:21:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.